COVID-19 Challenge — Point of Care and Home Diagnostic Kit for COVID-19 (Canada)
Deadline: 20 April 2020
The Public Health Agency of Canada (PHAC) and National Research Council (NRC) are seeking a solution that will diagnose individuals affected by COVID-19 within 3 days of the start of their symptoms using a sample, other than a nasopharyngeal swab, with a rapid single-use home testing kit analogous to a home pregnancy test.
(Ad) Are You Searching for Latest Grants, New Donors, Sample Proposals, Jobs and How to Apply Resources? fundsforNGOs Premium has all these and more at one place! Learn more.
Currently, COVID-19 testing is being performed by molecular detection using RT-PCR technology. This is occurring in large hospital-based or public health laboratories. This introduces several challenges, including sample routing (from patient to lab), requires specialized equipment and reagents (which can be in short supply) and requires specialized work force (which is vulnerable to illness from the pandemic). While there has been a concerted effort to mitigate these risks, they are insufficient. For example, decentralization of the testing to front-line labs increases capacity but also strains reagent resources. Alternatively, the validation and implementation of point-of-care diagnostics can extend capacity, provide rapid accurate results, and lower technology needs, but still require specialized instrumentation. This limits the ability to disseminate testing as far as would be ideal.
The proposed solution should:
(Ad) Stop getting irritated with excessing advertisements. View the information you want quickly on a clean, ad-free and exclusive Member Dashboard that offers tools to search for grants, view latest grant opportunities, upcoming deadlines, sample proposals, downloadable ebooks and also organize your favourites! Learn more.
Phase 1 requirements:
Detect SARS-CoV-2 (the causative agent of COVID-19) within the first 72 hours of symptoms with an accuracy similar to molecular RNA detection.
Results should be available 20 minutes (at most) from sample collection to diagnosis.
The sample input must be one other than a nasopharyngeal swab.
The device must be single use the following section has been added as a new requirement. or reusable as long as decontamination following the usage is easy and there is no complex disposal procedure of the previous test (e.g., it does not result in toxic waste).
The device price cannot exceed $40.
The device must be usable by a lay person with no technical training (although an instruction sheet is allowable).
The interpretation of the result should be easy for a lay person (i.e. negative or positive).
Each device should possess a unique identifier (i.e serial code, QR or bar code).
Phase 2 requirements:
Demonstrate, at the end of Phase 2, clinical efficacy data derived from a clinical trial comparing the device to the performance of the current gold standard. The gold standard is molecular detection by nasopharyngeal swab collection using two gene targets (the E and RdRp genes). Gold standard testing can be performed by the National Microbiology Laboratory or an accredited lab provided the samples are submitted in a blinded and anonimised fashion. Trial design should follow a non-inferiority trial design.
The proposed solution should:
(Ad) Are you still finding it difficult to search for donors online? Join Premium and use our powerful Donor Search mechanism to find relevant donors based on your country and location or keyword. Our specially developed algorithm will search across the internet for the most relevant and useful donors of your interest willing to fund your work. Learn more.
The result of the test should be easily uploaded to the public health system / network connected to enable monitoring and action. The result should also be easily uploaded as anonymous if desired.
Interpretation of the device result would benefit from assistance using commonly available technology, such as smart phone cameras, to facilitate interpretation of positive or negative results and record the result.
Funding of up to $300,000.00 CAD for up to 3 months could be available for any Phase 1 grant resulting from this Challenge.
Estimated number of Phase 1 grants to be awarded: 2
Funding of up to $2,000,000.00 CAD for up to 12 months could be available for any Phase 2 grant resulting from this Challenge. Only eligible businesses that received Phase 1 funding could be considered for Phase 2.
Estimated number of Phase 2 grants to be awarded: 1
This disclosure is made in good faith and does not commit Canada to award any grant for the total approximate funding. Final decisions on the number of Phase 1 and Phase 2 awards will be made by Canada on the basis of factors such as evaluation results, departmental priorities and availability of funds. Canada reserves the right to make partial awards and to negotiate project scope changes.
(Ad) Not able to keep track of so may different grant opportunities and their deadlines? No problem! fundsforNGOs Premium has a handy tool called « Deadline Calendar. » This tool will help you keep track of all upcoming grant opportunities and their deadlines and view them in a beautiful calendar format. Learn more.
Solution proposals can only be submitted by a small business that meets all of the following criteria:
incorporated in Canada (federally or provincially)
499 or fewer full-time equivalent (FTE) employees Footnote
research and development activities that take place in Canada
50% or more of its annual wages, salaries and fees are currently paid to employees and contractors who spend the majority of their time working in Canada Footnote
50% or more of its FTE employees have Canada as their ordinary place of work Footnote
50% or more of its senior executives (Vice President and above) have Canada as their principal residence
For more information, visit https://www.ic.gc.ca/eic/site/101.nsf/eng/00100.html